Abivax S.A.
FRValuation Metrics
Abivax S.A.'s Market Cap is $8.37B. At end of 2025 it was $919M. Ranked #1026 of 3,121 in US market (top 33%), #334 of 1,463 on NASDAQ (top 23%), #55 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.37B | US#1,026/3,121 Sec#55/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-380M | US—/3,121 Sec—/266 |
| Total Assets | $686M | US#2,641/3,121 Sec#134/266 |
| Net Assets | $535M | US#2,192/3,121 Sec#102/266 |
| Employees | 80 | US#2,665/3,121 Sec#192/266 |
| Value | ||
| P/B | 15.66x | US#2,749/3,121 Sec#212/266 |
| FCF Yield | -2.10% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -71.04% | US#2,756/3,121 Sec#189/266 |
| ROA | -55.34% | US#3,005/3,121 Sec#222/266 |
| Financial Health | ||
| Debt Ratio | 28.37% | US#312/3,121 Sec#100/266 |
| Total Debt | $54M | US#2,602/3,121 Sec#153/266 |
| FCF | $-176M | US#2,754/3,121 Sec#196/266 |
| Cash | $607M | US#950/3,121 Sec#46/266 |
| Current Ratio | 8.75x | US#299/3,121 Sec#90/266 |
| Performance | ||
| 1Y Return | 26.08% | US#867/3,121 Sec#138/266 |
| 1M Return | -12.87% | US#2,440/3,121 Sec#186/266 |
| From 52W High | -29.42% | US#1,963/3,121 Sec#154/266 |
| 1Y MDD | -50.11% | US#2,467/3,121 Sec#180/266 |
| Trading | ||
| Volume | 868,354 shares | US#1,304/3,121 Sec#140/266 |
| Trading Value | $91M | US#719/3,121 Sec#45/266 |
| Per Share | ||
| EPS | $-4.76 | US—/3,121 Sec—/266 |
| BPS | $6.71 | US#2,126/3,121 Sec#104/266 |
Company Info
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.